Government-Owned Inventions; Availability for Licensing, 10779-10780 [2017-03016]
Download as PDF
Federal Register / Vol. 82, No. 30 / Wednesday, February 15, 2017 / Notices
mstockstill on DSK3G9T082PROD with NOTICES
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
patent applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Synergistic Internal Ribosomal Entry
Site (IRES)—MicroRNA-Based
Approach for Attenuation of
Flaviviruses and Live Vaccine
Development
Description of Technology: Many
members of the Flaviviridae family are
emerging and reemerging human
pathogens that have caused outbreaks of
devastating and often fatal diseases and
represent a serious public health
problem on a global scale. There is no
single attenuation strategy that exists
which is sufficient to prepare a safe,
efficacious and immunogenic live
attenuated virus vaccine that will work
universally for Flaviviridae. This patent
application claims live attenuated
flavivirus vaccines, live attenuated
multivalent flavivirus vaccines, and
methods of preventing flavivirus
infections as well as methods of making
the vaccines claimed in the application.
More specifically, this patent
application claims methods for
attenuating a flavivirus or chimeric
flavivirus using a synergistic dual
strategy involving inserting miRNAtargeting sequences to restrict virus
replication in target hosts, cells and/or
tissues and placing one or more
flavivirus genes under translational
control of an internal ribosomal entry
site (IRES).
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Diagnostics
• Vaccines
Competitive Advantages:
VerDate Sep<11>2014
18:44 Feb 14, 2017
Jkt 241001
•
•
•
•
Potential one-dose flavivirus vaccine
Ease of manufacture in Vero cells
Low-cost potential vaccine
Developing and developed world
potential vaccines
Development Stage:
• In vivo data available (animal)
Inventors: Alexander Pletnev (NIAID),
Konstantin Tsetsarkin (NIAID).
Intellectual Property: HHS Reference
No. E–006–2017/0—U.S. Provisional
Application No. 62/443,214, filed
January 6, 2017.
Licensing Contact: Peter Soukas, J.D.,
301–594–8730; peter.soukas@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize vaccine(s) for
prophylaxis against flavivirus
infections. For collaboration
opportunities, please contact Peter
Soukas, J.D., 301–594–8730;
peter.soukas@nih.gov.
Dated: February 6, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–03017 Filed 2–14–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
patent applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
SUMMARY:
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
10779
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
A Bivalent Conjugate Vaccine for
Malaria and Typhoid Prophylaxis
Description of Technology: Malaria is
the single leading cause of mortality,
especially among children in the
developing world. Typhoid fever,
caused by infection with Salmonella
typhi, is known to be endemic with
malaria and causes its own significant
disease burden. Scientists at the
National Institute of Allergy and
Infectious Diseases (NIAID), part of the
National Institutes of Health, have
developed a novel bivalent vaccine
candidate that may effectively prevent
malaria and typhoid. This approach
significantly enhances immune
response to the Pfs25 Malaria
transmission blocking antigen and
produces a robust immune response
against Salmonella typhi Vi
polysaccharide (ViP).
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Development of this technology
into a vaccine may protect vulnerable
populations from both Malaria
transmission and Typhoid fever.
Competitive Advantages:
• This technology has significant
advantages over current treatments,
since there is currently only one
commercial Malaria vaccine licensed for
use in Europe only, which was not
developed to address Malaria
transmission, and the currently licensed
Salmonella typhi vaccines show
incomplete efficacy and do not provide
long-term immunity. A formulation of
the present technology has shown the
ability to induce an immune response to
Pfs25 in excess of 100 times higher and
Salmonella typhi antigen 20–40 times
higher than what is seen by
immunization with either antigen alone.
Development Stage:
• In vivo data available (animal).
Inventors: Drs. Patrick Duffy, Sojung
An, and Puthupparampil Scaria, NIAID,
NIH.
Publications: None.
Intellectual Property: Provisional
Patent application #62/327,184 Filed
04/25/16, Technology reference #E–
124–2016/0.
E:\FR\FM\15FEN1.SGM
15FEN1
10780
Federal Register / Vol. 82, No. 30 / Wednesday, February 15, 2017 / Notices
Licensing Contact: Daniel Anacker,
Ph.D., 301–761–7671, daniel.anacker@
nih.gov.
Collaborative Research Opportunity:
The NIAID, Laboratory of Malaria
Immunology and Vaccinology is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize this technology. Please
contact Dr. Daniel Anacker at 301–761–
7671 or daniel.anacker@nih.gov for
more information.
Dated: February 8, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–03016 Filed 2–14–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
[Docket No. DHS–2017–0005]
The President’s National Security
Telecommunications Advisory
Committee
Department of Homeland
Security.
ACTION: Committee Management; Notice
of Federal Advisory Committee Meeting.
AGENCY:
The President’s National
Security Telecommunications Advisory
Committee (NSTAC) will meet via
teleconference on Friday, March 3,
2017. The meeting will be open to the
public.
DATES: The NSTAC will meet on Friday,
March 3, 2017, from 12:00 p.m. to 1:00
p.m. Eastern Standard Time (EST).
Please note that the meeting may close
early if the committee has completed its
business.
ADDRESSES: The meeting will be held
via conference call. For access to the
conference call bridge, information on
services for individuals with
disabilities, or to request special
assistance to attend, please email
NSTAC@hq.dhs.gov by 5:00 p.m. EST
on Monday, February 27, 2017.
Members of the public are invited to
provide comment on the issues that will
be considered by the committee as listed
in the SUPPLEMENTARY INFORMATION
section below. Associated briefing
materials that participants may discuss
during the meeting will be available at
www.dhs.gov/nstac for review as of
Friday, February 24, 2017. Comments
may be submitted at any time and must
be identified by docket number DHS–
2017–0005. Comments may be
mstockstill on DSK3G9T082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:44 Feb 14, 2017
Jkt 241001
submitted by one of the following
methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Please follow the
instructions for submitting written
comments.
• Email: NSTAC@hq.dhs.gov. Include
the docket number DHS–2017–0005 in
the subject line of the email.
• Fax: (703) 235–5962, ATTN: Sandy
Benevides.
• Mail: Designated Federal Officer,
Stakeholder Engagement and Critical
Infrastructure Resilience Division,
National Protection and Programs
Directorate, Department of Homeland
Security, 245 Murray Lane, Mail Stop
0604, Arlington, VA 20598–0604.
Instructions: All submissions received
must include the words ‘‘Department of
Homeland Security’’ and the docket
number for this action. Comments
received will be posted without
alteration at www.regulations.gov,
including any personal information
provided.
Docket: For access to the docket and
comments received by the NSTAC,
please go to www.regulations.gov and
enter docket number DHS–2017–0005.
A public comment period will be held
during the conference call on Friday,
March 3, 2017, from 12:40 p.m. to 12:55
p.m. EST. Speakers who wish to
participate in the public comment
period must register in advance and can
do so by emailing NSTAC@hq.dhs.gov
no later than Monday, February 27,
2017, at 5:00 p.m. EST. Speakers are
requested to limit their comments to
three minutes and will speak in order of
registration. Please note that the public
comment period may end before the
time indicated, following the last
request for comments.
FOR FURTHER INFORMATION CONTACT:
Helen Jackson, NSTAC Designated
Federal Officer, Department of
Homeland Security, (703) 235–5321
(telephone) or helen.jackson@
hq.dhs.gov (email).
SUPPLEMENTARY INFORMATION: Notice of
this meeting is given under the Federal
Advisory Committee Act, 5 U.S.C.
appendix (Pub. L. 92–463). The NSTAC
advises the President on matters related
to national security and emergency
preparedness (NS/EP)
telecommunications and cybersecurity
policy.
Agenda: The NSTAC will hold a
conference call on March 3, 2017, to
discuss issues and challenges related to
NS/EP communications, which will
include discussions with high-level
Government stakeholders and a review
of ongoing NSTAC work, including an
update on the NSTAC Emerging
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
Technologies Strategic Vision
Subcommittee’s study of the near- and
longer-term NS/EP implications of
emergent and expected information and
communications technologies.
Dated: February 2, 2017.
Helen Jackson,
Designated Federal Officer for the NSTAC.
[FR Doc. 2017–03009 Filed 2–14–17; 8:45 am]
BILLING CODE 9110–9P–P
INTERNATIONAL BOUNDARY AND
WATER COMMISSION UNITED
STATES AND MEXICO
United States Section; Notice of
Availability of a Final Environmental
Assessment and Finding of No
Significant Impact for Alamito and
Terneros Sediment and Vegetation
Removal Below Presidio Flood Control
Project, Presidio, Texas
United States Section,
International Boundary and Water
Commission, United States and Mexico.
ACTION: Notice of Availability of the
Final Environmental Assessment (EA)
and Finding of No Significant Impact
(FONSI).
AGENCY:
Pursuant to Section 102(2)(c)
of the National Environmental Policy
Act of 1969; the Council on
Environmental Quality Final
Regulations (40 CFR parts 1500 through
1508); and the United States Section,
Operational Procedures for
Implementing Section 102 of NEPA,
published in the Federal Register
September 2, 1981 (46 FR 44083); the
United States Section hereby gives
notice that the Final Environmental
Assessment and Finding of No
Significant Impact (FONSI) for Alamito
and Terneros Sediment and Vegetation
Removal below Presidio Flood Control
Project, Presidio, Texas is available. An
environmental impact statement will
not be prepared unless additional
information which may affect this
decision is brought to our attention
within 30-days from the date of this
Notice.
FOR FURTHER INFORMATION CONTACT:
Gilbert Anaya, Division Chief,
Environmental Management Division;
United States Section, International
Boundary and Water Commission; 4171
N. Mesa, C–100, El Paso, Texas 79902.
Telephone: (915) 832–4702, email:
Gilbert.Anaya@ibwc.gov.
Background: This Final
Environmental Assessment analyzes the
potential impacts of removing
accumulated sediment from Alamito
and Terneros Creeks at their confluence
SUMMARY:
E:\FR\FM\15FEN1.SGM
15FEN1
Agencies
[Federal Register Volume 82, Number 30 (Wednesday, February 15, 2017)]
[Notices]
[Pages 10779-10780]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-03016]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the patent applications listed below may be obtained by communicating
with the indicated licensing contact at the Technology Transfer and
Intellectual Property Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required
to receive copies of unpublished patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
A Bivalent Conjugate Vaccine for Malaria and Typhoid Prophylaxis
Description of Technology: Malaria is the single leading cause of
mortality, especially among children in the developing world. Typhoid
fever, caused by infection with Salmonella typhi, is known to be
endemic with malaria and causes its own significant disease burden.
Scientists at the National Institute of Allergy and Infectious Diseases
(NIAID), part of the National Institutes of Health, have developed a
novel bivalent vaccine candidate that may effectively prevent malaria
and typhoid. This approach significantly enhances immune response to
the Pfs25 Malaria transmission blocking antigen and produces a robust
immune response against Salmonella typhi Vi polysaccharide (ViP).
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
Development of this technology into a vaccine may protect
vulnerable populations from both Malaria transmission and Typhoid
fever.
Competitive Advantages:
This technology has significant advantages over current
treatments, since there is currently only one commercial Malaria
vaccine licensed for use in Europe only, which was not developed to
address Malaria transmission, and the currently licensed Salmonella
typhi vaccines show incomplete efficacy and do not provide long-term
immunity. A formulation of the present technology has shown the ability
to induce an immune response to Pfs25 in excess of 100 times higher and
Salmonella typhi antigen 20-40 times higher than what is seen by
immunization with either antigen alone.
Development Stage:
In vivo data available (animal).
Inventors: Drs. Patrick Duffy, Sojung An, and Puthupparampil
Scaria, NIAID, NIH.
Publications: None.
Intellectual Property: Provisional Patent application #62/327,184
Filed 04/25/16, Technology reference #E-124-2016/0.
[[Page 10780]]
Licensing Contact: Daniel Anacker, Ph.D., 301-761-7671,
daniel.anacker@nih.gov.
Collaborative Research Opportunity: The NIAID, Laboratory of
Malaria Immunology and Vaccinology is seeking statements of capability
or interest from parties interested in collaborative research to
further develop, evaluate, or commercialize this technology. Please
contact Dr. Daniel Anacker at 301-761-7671 or daniel.anacker@nih.gov
for more information.
Dated: February 8, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-03016 Filed 2-14-17; 8:45 am]
BILLING CODE 4140-01-P